Announced Date: 2025-12-15 (December 15, 2025) Licensor (Seller): Innolake Biopharm (Innolake, 因诺湖) (China) Licensee (Buyer): Ellipses … [China BD 2026]Read more
China License Out
[China BD 2025] GeneScience and Yarrow Bioscience (RTW) Entered a 1.4 Billion USD License for Anti-TSHR Antibody GenSci098 (YB-101)
Announced Date: 2025-12-15 (December 15, 2025) Licensor (Seller): Shanghai Scizeng Medical Technology, a subsidiary of Changchun … [China BD 2025] GeneScience and Yarrow Bioscience (RTW) Entered a 1.4 Billion USD License for Anti-TSHR Antibody GenSci098 (YB-101)Read more
[China BD 2025] Fosun Pharma’s Subsidiary Yao Pharma and Pfizer Enter into a 2 Billion USD License on GLP-1R Agonists YP05002
Announced Date: 2025-12-09 (December 9, 2025) Licensor (Seller): Chongqing Yao Pharmaceutical, Subsidiary of Fosun Pharma (China) … [China BD 2025] Fosun Pharma’s Subsidiary Yao Pharma and Pfizer Enter into a 2 Billion USD License on GLP-1R Agonists YP05002Read more
[China BD 2025] Kelun-Biotech and Crescent Biopharma enter License and Collaboration on ITGB6 ADC SKB105 (CR-003)
Announced Date: 2025-12-04 (December 4, 2025) Licensor (Seller): Kelun-Biotech (China) Licensee (Buyer): Crescent Biopharma (US) (Nasdaq: … [China BD 2025] Kelun-Biotech and Crescent Biopharma enter License and Collaboration on ITGB6 ADC SKB105 (CR-003)Read more
[China BD 2025] Degron Therapeutics and MSD enters a License on FIC Molecular Glue Degraders
Announced Date: 2025-11-13 (November 11, 2025) Licensor (Seller): Degron Therapeutics (China) Licensee (Buyer): MSD R&D (China) … [China BD 2025] Degron Therapeutics and MSD enters a License on FIC Molecular Glue DegradersRead more
[China BD 2025] TransThera and Neurocrine Enters a 882 USD Million License on NLRP3 Inhibitor Program
Announced Date: 2025-11-03 (November 3, 2025) Licensor (Seller): TransThera Sciences (China) Licensee (Buyer): Neurocrine Biosciences (US) … [China BD 2025] TransThera and Neurocrine Enters a 882 USD Million License on NLRP3 Inhibitor ProgramRead more
[China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1/GIP/FGF21 Agonist Peptides MWN105
Announced Date: 2025-10-31 (October 31, 2025) Asset Name: MWN105 Licensor (Seller): Shanghai Minwei Biotech, subsidiary of … [China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1/GIP/FGF21 Agonist Peptides MWN105Read more
[China BD 2025] Qyuns Therapeutics and Roche Entered a 107 Million USD License for TSLP/IL-33 Bispecific Antibody QX031N
Announced Date: 2025-10-28 (October 28, 2025) Asset Name: QX031N Licensor (Seller): Qyuns Therapeutics (China) Licensee (Buyer): … [China BD 2025] Qyuns Therapeutics and Roche Entered a 107 Million USD License for TSLP/IL-33 Bispecific Antibody QX031NRead more
[China BD 2025] Innovent Biologics and Takada enters 11.4 Billion USD License and Collaboration Agreement on Three Oncology Assets, IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7H3 ADC)
Announced Date: 2025-10-21 (October 21, 2025) Asset Name: IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC)，IBI3001 (EGFR/B7H3 ADC) Licensor … [China BD 2025] Innovent Biologics and Takada enters 11.4 Billion USD License and Collaboration Agreement on Three Oncology Assets, IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7H3 ADC)Read more
[China BD 2025] Pregene Biopharma and KitePharma (Gliead) enters a 1.64 Billion USD License on In vivo CAR-T
Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): Pregene Biopharma (China) Licensee (Buyer): KitePharma (Gliead) . … [China BD 2025] Pregene Biopharma and KitePharma (Gliead) enters a 1.64 Billion USD License on In vivo CAR-TRead more